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Abstract
This study aimed to evaluate mortality within 365 days of HbA1c values of ,6.5% or.9.0% in participants with clinical type
2 diabetes mellitus. A matched nested case-control study was implemented, within a cohort of participants with type 2
diabetes from 2000 to 2008. Conditional logistic regression was used to model the odds ratio for mortality adjusting for
comorbidity and drug utilisation. There were 97,450 participants with type 2 diabetes; 16,585 cases that died during follow
up were matched to 16,585 controls. The most recent HbA1c value was,6.5% (48 mmol/mol) for 22.2% of cases and 24.2%
of controls, the HbA1c was .9.0% for 9.0% of cases and 7.7% of controls. In a complete case analysis, the adjusted odds
ratio (AOR) for mortality associated with most recent HbA1c ,6.5% was 1.31 (95% confidence interval (CI): 1.21,1.42). After
multiple imputation of missing HbA1c values the AOR was 1.20 (CI: 1.12,1.28). The complete case analysis gave an AOR for
HbA1c .9.0% of 1.51 (CI: 1.33, 1.70), in the multiple imputation analysis this was 1.29 (1.17,1.41). The risk associated with
HbA1c ,6.5% was age dependent. In the multiple imputation analysis the AOR was 1.53 (CI: 0.84 to 2.79) at age,55 years
but 1.04 (CI: 0.92, 1.17) at age 85 years and over. In non-randomised data, values of HbA1c that are either ,6.5% or .9.0%
may be associated with increased mortality within one year in clinical type 2 diabetes. Relative risks may be higher at
younger ages.
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Introduction
Diabetes represents a major public health concern and efforts to
control hyperglycaemia are an important element of the manage-
ment of patients with type 2 diabetes [1]. Hyperglycaemia is
measured using haemoglobin A1c (HbA1c) test which assesses the
average level of blood glucose in the preceding 60–120 days. For
diabetes patients an HbA1c target of 6.5% (48 mmol/mol) is
recommended [2,3] on the basis that lowers the risk of developing
diabetic complications (i.e. kidney disease, heart disease). The UK
Prospective Diabetes Study (UKPDS) established that intensive
control of blood glucose in type 2 diabetes reduced the risk of
microvascular complications, especially diabetic retinopathy, in
patients with type 2 diabetes [4]. While the UKPDS did not find
any effect of intensive blood glucose lowering on cardiovascular
events, these were also found to be reduced during post-trial
follow-up [5]. A systematic review of five trials confirmed that
cardiovascular events were reduced through intensive control [6].
However, hypoglycaemia is a recognized hazard of intensive
therapy, being more frequent in intensively treated patients [7].
Recent evidence suggests that hypoglycaemia may also be
associated with adverse vascular events and all-cause mortality
[7,8]. The ACCORD study [9] found that intensive lowering of
blood glucose (HbA1c target of 6.0%) was not associated with
reduced cardiovascular events, but there was an increase in all-
cause mortality in type 2 diabetic subjects at high risk of
cardiovascular disease (CVD). A subsequent analysis of data from
the ADVANCE study [10] suggested that there might be a
threshold for the beneficial effect of glucose lowering with no
benefit observed from reducing HbA1c below 7% for macro-
vascular events and mortality or below 6.5% for microvascular
events [11].
Recently, Currie et al. [12] reported that either very high or
very low HbA1c increased the risk of all-cause mortality in a large
cohort of patients routinely treated in UK primary care. Their
primary analysis did not allow for changes in HbA1c over time
and instead used the mean of all HbA1c values subsequent to the
index date. Although further time dependent analysis were carried
out using yearly mean HbA1c, missing data was dealt with using
last observation carried forward which can result in bias. This is a
potentially important limitation, as Currie et al. [12] did not
report on the completeness of HbA1c records and these may not
have been routinely recorded during the period they examined
(1986 to 2008). Riveline et al. [13] also noted that Currie et al.’s
population may have had substantial heterogeneity since the
UKPDS trial has led to significant changes in the management of
Type 2 diabetes (i.e. risk modeling, health economics). In addition,
existing treatment targets for HbA1C set by the NICE
(HbA1C,7%) (2008) or the American Diabetes Association
(HbA1C,7%) (2008) are not age specific and Pani et al. [14]
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underlined the importance of establishing whether age-specific
treatment criteria would be appropriate.
This study aimed to evaluate short-term associations between
HbA1c values recorded in clinical practice in primary care and
subsequent risk of mortality in a post-UKPDS population. A case
control study was implemented to establish an explicit temporal
link between HbA1c values recorded in the previous 365 days and
mortality risk, rather than utilizing HbA1c records that might
cover a considerable length of time, as has been done previously
[12]. We aimed to determine whether the risk of mortality was
higher when the most recent HbA1c value in the preceding 365
days was either ,6.5% or .9.0% compared to HbA1c values that
were between 6.5% and 9%. Considering the scarce evidence for a
possible age-depended influence of HbA1C levels on mortality
[14], an additional aim of the present study was to explore
potential age-associated differences in mortality rates for both low
and high HbA1C levels.
Methods
A nested case-control study was implemented using data from
family practices contributing to the Clinical Practice Research
Datalink (CPRD, formerly known as the General Practice
Research Database) between 1 July 2000 and 30 April 2008.
The CPRD contains comprehensive information on patients’
medical diagnoses, drug prescriptions, lifestyle advice, specialist
referrals, laboratory tests, hospital admissions, and clinical findings
(i.e. BMI, smoking, and blood pressure). For entry into the GPRD,
practice data must be up to standard (UTS) for research as set out
by the GPRD group. The validity of CPRD data for diagnoses and
prescribing has been documented in several studies [15,16]. Data
for the present study was based on a research project developed in
2009 and thus the latest available data for analysis was to the end
of December, 2008.
The case-control study was nested in a cohort of people with
type 2 diabetes. A case-control design was preferred because it is
more efficient than a cohort design for a rare outcome such as
mortality. The study also intended to validate Currie et al.’s [12]
findings by using a different approach to design. Participants were
included in the cohort if they had ever been diagnosed with
diabetes mellitus, or prescribed oral hypoglycemic drugs or insulin.
Date of diabetes onset was defined as the earlier of first recorded
medical or referral code for diabetes or first date of prescription of
oral hypoglycemic drugs or insulin. Participants were excluded if
they had ever been diagnosed with type 1 diabetes mellitus; were
aged less than 30 years at diabetes onset; or were prescribed insulin
within 180 days of diabetes onset. Participant follow-up started
from the later of: date of onset of diabetes, date of registration with
a CPRD practice, date at which the practice began contributing
UTS data to CPRD, or 1 July 2000. Participants were censored
when they transferred out of a CPRD practice, at the last date at
which their practice contributed up to standard (UTS) data to
CPRD, or on 30 April 2008.
Cases were participants who died while on follow-up in the
cohort. For each eligible case, one control was randomly selected
from the study cohort matched by gender, age category (,35, 35
to 44, 45 to 54, 55 to 64, 65 to 74, 75 to 84, 85+ years), and time
since cohort entry (,90; 90 to 179; 180 to 364, 365+ days).
Additional matching variables were considered unnecessary and
might have resulted in overmatching. In addition, the study was
sufficiently large to allow regression adjustment for multiple
confounding variables [17]. One control per case was preferred as
with large sample sizes as in the present study there is little gain in
statistical power by including more than one control per case [18].
Each control was assigned the index date of their matched case.
Measures
To evaluate both recent HbA1c and recent change in HbA1c
the latest two values in the 365 days preceding the index date were
identified. HbA1c values below 2.5% or over 25% were discarded
as these values were considered implausible. The most recent
HbA1c test results in the 365 days before the index date was used
as the primary exposure and was classified as ‘low’ (HbA1c less
than 6.5%), ‘normal’ (HbA1c between 6.5% and 9.0% mol/mol)
or ‘high’ (HbA1c greater than 9.0%). A value of 6.5% is a
commonly employed cut-off point in studies exploring HbA1c
levels and mortality association [19,20]. For instance, Zoungas
et al. [20] suggested the 6.5% as the threshold above which there
is an increase risk in microvascular events and death in diabetes
patients. The same cut-point has also been recommended as a
target for Type diabetes [2,3]. The 9% cut-off point has been
suggested to represent an indicator for ineffective blood glucose
management in type 2 diabetes [3,21]. Change in HbA1c
represented the difference between the most recent value and
the preceding HbA1c value if this was also recorded within 365
days of the index date. Change was classified as a decrease in
HbA1c (decline in HbA1c of greater than 21%), no or marginal
change (change between 21% and 1%), or increase in HbA1c
(increase in HbA1c of greater than 1%).
To adjust for potential confounders of the relationship between
HbA1c and mortality we identified diagnoses in the last 365 days
of: coronary heart disease, arrhythmia, heart failure, stroke or
transient ischemic attack, cancer, hypertension, renal failure, liver
disease and malnutrition or malabsorption. Analysis also adjusted
for treatment with lipid lowering therapies, including statins,
within the last 365 days, most recent smoking status (3 categories:
non-smoker, ex-smoker, current smoker) and BMI value recorded
within the last 365 days (3 categories: normal/underweight,
overweight, obese), and treatment with glucose lowering medica-
tions within 180 days (insulins, sulphonylureas, biguanides,
pioglitazone, rosiglitazone, and other hypoglycemic medications).
The 365 days time frame was informed by the likelihood that
severe chronic illnesses will be monitored on at least yearly basis
and thus using a 365 days period would allow identification of all
patients previously diagnosed with a severe chronic condition. The
use of 180 days period for drug therapy was based on the typical
length of prescriptions in CPRD. The aim was to capture
information concerning glucose therapy at the time of death.
Participants who were not prescribed glucose lowering drugs were
assumed to be on therapy with diet or exercise, though these
interventions are not comprehensively recorded in GPRD.
Statistical Analysis
Data were analyzed using conditional logistic regression in Stata
MP version 11.2 (Stata corporation, College Station, Texas, USA)
to estimate the association of mortality with low and high HbA1c
levels using normal HbA1c level as the reference category. The
initial model included adjustment only through matching (gender,
age, time since cohort entry). The final model adjusted for all
confounders listed above. The confounders were entered into the
model as categorical explanatory variables. In order to evaluate
effect modification, analyses were also carried out stratified by age
group (age at index date: ,55, 55–64, 65–74, 75–84, 85+ years).
As with the primary analysis, conditional logistic regression models
were fitted with and without adjustment for possible confounders
of the relationship between HbA1c and mortality.
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Missing Data
Initial models used complete case analysis and included only
matched sets where both the case and control had a valid HbA1c
test result within the 365 days prior to the index date. For models
examining change in HbA1c values, the complete case analysis
included only matched sets where both the case and control had
two valid HbA1c test results within the 365 days prior to the index
date.
To evaluate the impact of missing data, multiple imputation was
used to replace any missing values for the most recent two HbA1c
tests. Multiple imputation was used to replace missing values for
smoking status and BMI for patients without a record of these data
in the previous 365 days. Multiple imputation was preferred
because it is superior to other missing data approaches (i.e. mean
replacement, last observation) even in situations where a large
proportion of the data is missing [22]. Also, removing patients with
missing data from the study (i.e. listwise) would result in a
significant loss of the study sample, raising concerns about the
validity of the results [23]. Data were imputed using multiple
imputation by chained equations, which allows an appropriate
imputation model to be defined for each variable. The ‘‘mi impute
chained’’ command in Stata was used to implement predictive
mean matching for HbA1c tests, and multinomial logistic
regression for smoking and BMI category. Ten imputed datasets
were generated. Predictive mean matching replaces each missing
value by the observed value with the closest match on predicted
value from the imputation regression model. Predictive mean
matching was used as it is considered more robust to violation of
the normality assumption of the regression model underlying the
multiple imputation procedure and ensures that imputed values
will be within the range of observed values [24]. Multinomial
logistic regression was selected for imputing missing values for
smoking and BMI category because these were constructed as a
multinomial categorical variable (e.g. never smoked, ex-smoker,
current smoker).
Results
The cohort of participants included 97,450 participants from
226 family practices, who were followed up for a total of 386,738
person years (median 3.7 years per participant). All 16,585 cases
that died during follow-up were matched to a suitable control and
were included in the analyses. Participant characteristics for cases
and controls are presented in Table 1. Cases tended to have
marginally longer duration of diabetes relative to controls. Also a
greater proportion of cases than controls were treated with insulin
or sulphonylureas and a lower proportion were treated with
biguanides, pioglitazone or rosiglitazone. A greater proportion of
cases than controls had diagnosis in the prior 365 days of coronary
heart disease, heart failure, stroke or transient ischemic attack,
cancer, malnutrition or malabsorption, renal failure and liver
disease. A smaller proportion of cases than controls had diagnosis
of hypertension or treatment with lipid lowering medications. In
addition, cases were more likely to be recorded as smokers and
weigh less than controls.
At least one valid value of HbA1c was recorded in the 365 days
before the index date for 79.9% of controls and 67.5% of cases
(Table 2). Change in the last 365 days could be calculated for the
45.1% of controls and 33.0% of cases. Although mean HbA1c was
higher for cases than controls, the average change in HbA1c was
similar (0.14).
The complete case analysis revealed that higher HbA1c (.9%
or 75 mmol/mol) values were associated with increased odds (OR
1.58, CI: 1.37,1.82) of all-cause mortality. Low HbA1c (,6.5%)
values were also associated with increased odds of all-cause
mortality (OR=1.22, CI: 1.11,1.34) in comparison to normal
HbA1c levels after adjustment for study confounders (Table 3).
Since not all cases and controls had a valid HbA1c test result in the
last 365 days, only 9,241 of the total of 16,585 pairs of matched
case and controls were available for the complete case analysis.
Participants with missing HbA1c values were more likely to be
cases and were also younger, less intensively treated with lipid
lowering medications and diabetes medications, less likely to have
diagnosis of CHD, heart failure, renal disease or hypertension and
had shorter length of follow-up time at their index date. Therefore,
it appears unlikely that data were missing completely at random
and so it is possible that bias may be present in the complete case
analysis. Multiple imputation analyses results also suggested that
both low and high HbA1c levels were associated with increased
risk of mortality in comparison to normal HbA1c levels (Table 3),
but the effect sizes were somewhat smaller relative to the complete
case analysis.
From the complete case model and multiple imputation model,
changes in HbA1c within the last 365 days also appeared to be
associated with increased mortality risk. Adjusting for study
confounders, decreasing HbA1c levels prior to death were
associated with 1.50 (CI: 1.11, 2.02) greater odds of all-cause
mortality compared to no HbA1c levels change. A lower and effect
size was observed with respect to increasing HbA1c levels
(OR=1.39, CI: 1.10,1.75). Fully specified models are detailed in
the Supplementary material (Table S1 in File S1).
When the association between HbA1c and mortality was
examined separately by age group, both the complete case
analysis and multiple imputation models indicated that both low
and high HbA1c was significantly associated with increased risk of
mortality among participants aged 55 to 74 (Table 4). In addition,
multiple imputation results indicated that high HbA1c (.9%)
were significantly associated with increased risk of all-cause
mortality (OR=1.29, CI: 1.08,1.53) among the 75 to 84 age
groups compared to normal HbA1c (6.5% to 9%). Both complete
case analysis and multiple imputation models indicated that the
odds ratio for low HbA1c (,6.5%) was greatest in participants
aged less than 55 years old (2.05 (CI: 0.83,5.06) for complete case
analysis and 1.53 (CI:0.84,2.79) for multiple imputation), and
declined steadily with older age to become close to one for
participants aged 85 and older (1.05 (CI:0.87,1.26) for complete
case analysis and 1.04 (CI:0.92,1.17) for multiple imputation). A
similar declining trend with age was observed with respect to high
HbA1c levels (apart from the youngest age group). Fully specified
models are detailed in the Supplementary material (Table S2 in
File S1).
Discussion
In a population-based study it was revealed that both low and
high HbA1c values are associated with increased short-term risk of
all-cause mortality. In adults diagnosed with diabetes in primary
care there was a 60% increase in the odds of all-cause mortality
associated with high HbA1c levels and a 40% increase in the odds
of all-cause mortality associated with low HbA1c levels. Employing
a post-UKPDS population, the study also demonstrates that both
increases and decreases in HbA1c values prior to death are
associated with increased risk of mortality.
A possible age-associated effect for the relationship between
HbA1c and mortality risk was observed. In particular, the strength
of the association between HbA1c levels and all-cause mortality
showed a consistent decline from younger age group (,55 years of
age) to the older age group (.85 years of age) suggesting a possible
HbA1c Values and Mortality Risk
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Table 1. Participant characteristics for cases and controls.
Variable Controls (n =16585) Cases (n=16585)
Male 8569 (51.7) 8569 (51.7)
Age at index date, years
,45 79 (0.5) 79 (0.5)
45 to 54 353 (2.1) 353 (2.1)
55 to 64 1378 (8.3) 1378 (8.3)
65 to 74 3842 (23.2) 3842 (23.2)
75 to 85 6496 (39.2) 6496 (39.2)
85+ 4437 (26.8) 4437 (26.8)
Duration diabetes (years)a 5.5 (2.25, 10.63) 6.3 (2.55, 11.99)
Duration of follow-up (years)a 2.4 (1.00, 4.33) 2.5 (1.00, 4.44)
Year of death
2000 847 (5.1) 847 (5.1)
2001 1858 (11.2) 1858 (11.2)
2002 2057 (12.4) 2057 (12.4)
2003 2154 (13.0) 2154 (13.0)
2004 2184 (13.2) 2184 (13.2)
2005 2315 (14.0) 2315 (14.0)
2006 2447 (14.8) 2447 (14.8)
2007 2478 (14.9) 2478 (14.9)
2008 245 (1.5) 245 (1.5)
Smoking status
Non-smoker 7348 (44.3) 6312 (38.1)
Ex-smoker 6795 (41.0) 6451 (38.9)
Current-smoker 1657 (10.0) 2382 (14.4)
Missing 785 (4.7) 1440 (8.7)
BMI category
Normal/underweight (BMI ,25) 4297 (25.9) 5218 (31.5)
Overweight (25#BMI ,30) 6124 (36.9) 4736 (28.6)
Obese (BMI$30) 4802 (29.0) 3771 (22.7)
Missing 1362 (8.2) 2860 (17.2)
Glucose-lowering therapy in 180 days before index date:
Insulins 1328 (8.0) 2077 (12.5)
Sulphonylureas 6619 (39.9) 7254 (43.7)
Biguanides 6484 (39.1) 5531 (33.3)
Pioglitazone 270 (1.6) 167 (1.0)
Rosiglitazone 694 (4.2) 544 (3.3)
Other glucose lowering medications 253 (1.5) 234 (1.4)
Dietary advice onlyb 946 (5.7) 797 (4.8)
Diagnoses & treatments 365 days before index date
Coronary heart disease 1099 (6.6) 2799 (16.9)
Arrhythmia 258 (1.6) 322 (1.9)
Heart failure 469 (2.8) 2176 (13.1)
Stroke or transient ischemic attack 350 (2.1) 1410 (8.5)
Hypertension 2820 (17.0) 1802 (10.9)
Cancer 818 (4.9) 3610 (21.8)
Malnutrition or malabsorption 97 (0.6) 204 (1.2)
Renal failure 297 (1.8) 1177 (7.1)
Liver disease 32 (0.2) 345 (2.1)
Treatment with lipid lowering medications 8064 (48.6) 6448 (38.9)
Values are frequency (percent) unless otherwise stated.
afigures are medians (interquartile range).
bNo glucose lowering drugs were prescribed for these diabetes patients and most these patients were possible referred to dietary and exercise support.
doi:10.1371/journal.pone.0068008.t001
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age-associated impact of HbA1c on all-cause mortality. Interest-
ingly, for older people (75 to 84 years old) only high HbA1c values
were significantly associated with increased risk of mortality.
Current treatment recommendations for type 2 diabetes do not
take into account patients’ age and the findings of the present
study suggest that younger and older diabetes patients may benefit
from different HbA1c treatment targets.
Although the mortality risks were elevated at all ages, the results
are presented by age because of the clinical importance. Higher
relative mortality at younger ages may be expected because deaths
from other causes are less frequent, while in older age high death
rates from other background causes are expected.
The finding that high HbA1c levels are associated with
increased risk of mortality could be partially explained by the
fact that high HbA1c levels are associated with increased risk of
diabetic macrovascular and microvascular complications [25,26].
These may contribute to deteriorating kidney function and anemia
have also been suggested to account for increased risk of mortality
associated with increased levels of HbA1c [14]. The association of
low HbA1c with mortality might be explained through hypogly-
caemia [27] or through association with liver disease [28]. Low
HbA1c values may sometimes indicate the presence of morbidity
and worse health.
Currie et al. [12] found that both high and low HbA1c levels
may increase the risk of all-cause mortality. The present study
substantiates the findings of Currie et al. [10] in a post-UKPDS
population and extends them by documenting a possible age-
associated relationship of HbA1c levels with the risk of all-cause
mortality. Currie et al. [12] study includes older patients (aged 50
years and above) and thus it was not possible to explore whether
the observed association between HbA1c and mortality in older
patients extends to younger diabetes patients. Our study findings
imply that intensive HbA1c lowering therapy increases mortality
risk across the age continuum, but also that the greater relative risk
was observed in younger (,55 years of age) diabetes patients. The
findings of the present study also appear to be consistent with those
found in the ACCORD and VADT trials [29,30]. In an earlier
study, Gerstein et al. [25] suggested that stringent HbA1c levels
might cause an excess risk of all-cause mortality. By contrast, Ray
et al. [31] in a recent meta-analysis of five RCTs concluded that a
decrease in HbA1c levels were not associated with reducing risk of
all-cause mortality. More recently, Boussageon et al. [32] and
Hemmingsen et al. [33] reached a similar conclusion in two meta-
analyses of RCTs. The present study raises questions concerning
the application of trial evidence to a wider primary care. By
addressing some of the previous studies methodological problems,
the present study helps clarify the current debate and established
that both high and low HbA1c level can be associated with an
increased risk for all-cause mortality.
This study has notable strengths including the consideration of
different HbA1c levels and short-term changes in HbA1c values
with use of multiple imputation to explore potential bias from
missing values, to provide evidence about the impact of HbA1c on
Table 2. Mean values and change in HbA1c in the last 365
days prior to the index date in cases and controls.
Controls Cases
(n=16585) (n =16585)
Most recent HbA1c test in the last 365 days
Mean (standard deviation) 7.21 (1.38) 7.32 (1.66)
,6.5% (48 mmol/mol) 4018 (24.2) 3677 (22.2)
6.5% to 9.0% (48 to 75 mmol/mol) 7962 (48.0) 6040 (36.4)
.9.0% (75 mmol/mol) 1272 (7.7) 1485 (9.0)
Missing 3333 (20.1) 5383 (32.5)
Change in HbA1c between two most recent tests in last 365 days
Mean change (standard deviation) 0.14 (0.97) 0.14 (1.20)
Decrease (decline of more than 21%) 439 (2.6) 517 (3.1)
No change (between 21% and 1%) 6231 (37.6) 4171 (25.2)
Increase (increase of greater than 1%) 818 (4.9) 779 (4.7)
Missing 9097 (54.9) 11118 (67.0)
Values are number (percent) unless otherwise stated.
doi:10.1371/journal.pone.0068008.t002
Table 3. Association between mortality and HbA1c.
Model Complete case Analysis Multiple Imputation
Matched OR Adjusted ORa Matched OR Adjusted ORa
(95% CI) (95% CI) (95% CI) (95% CI)
Model 1: Most recent HbA1c
Number of matched pairs 9241 7902 16585 16585
,6.5%b 1.21 (1.14, 1.29) 1.22 (1.11, 1.34) 1.14 (1.08, 1.20) 1.12 (1.04, 1.20)
.9.0%b 1.62 (1.46, 1.78) 1.58 (1.37, 1.82) 1.40 (1.29, 1.53) 1.29 (1.16, 1.44)
Model 2: Most recent value and change in HbA1c
Number of matched pairs 2739 2481 16585 16585
,6.5%b 1.24 (1.10, 1.41) 1.28 (1.08, 1.51) 1.16 (1.10, 1.22) 1.13 (1.05, 1.21)
.9.0%b 1.52 (1.25, 1.85) 1.46 (1.11, 1.91) 1.31 (1.19, 1.43) 1.23 (1.09, 1.37)
Decreasec 1.55 (1.24, 1.93) 1.50 (1.11, 2.02) 1.28 (1.13, 1.45) 1.21 (1.01, 1.45)
Increasec 1.58 (1.33, 1.87) 1.39 (1.10, 1.75) 1.25 (1.14, 1.38) 1.16 (1.03, 1.30)
Figures are odds ratios (OR), 95% confidence intervals (CI).
aadjusted for comorbidity, lipid lowering medication, smoking, BMI and diabetes drug utilisation.
b6.5% to 9.0% as reference category.
c‘no change’ as reference category.
doi:10.1371/journal.pone.0068008.t003
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mortality in a nationally representative cohort of diabetic patients.
However, several limitations are worth mentioning. The study did
not include information on patients’ exercise or dietary habits
which may modify medication effects and might partially explain
associations with mortality. We did not explore whether stable or
changing HbA1c levels are more strongly associated with
mortality. It is possible that the association of low HbA1c levels
with mortality could mask rather unstable HbA1c levels over time.
The findings that both increased and decreased HbA1c levels were
associated with higher mortality likelihood point towards such
possibility. Causes of death were not available for analysis limiting
our ability to explore whether disorders of blood glucose were
immediately related to patient death or whether other conditions
including comorbid disorders or fatal accidents may be responsible
for greater mortality rates in this population. Adjusting for
comorbid disorders ensured however that comorbidity might not
be the sole explanations for the findings.
The small proportion of patients who experienced a decrease or
increase in HbA1c values between the last two measurements
limited our ability to conduct more detailed analyses such the
effect of decrease or increase in HbA1c values within the low
(,6.5%) and high (.9.0%) categories. The study cannot rule out
the possibility of residual confounding which may explain the
observed association between Hb1Ac and mortality. Additionally,
because of the inconsistent recording of dietary data in CPRD it
was not possible to compare the reduction in HbA1c levels due to
diet or medication. However, most patients on diabetes medica-
tion will also be offered dietary advice, making difficult any
definite distinction about differential reduction in HbA1c levels
between diet and medication in observational studies.
It is likely that mortality risks may differ for different drugs and
drug combinations and several studies [34,35] have linked
sulphonylurea drugs with increased mortality and glitazone
therapy with increased risk of cardiovascular events [36,37].
These are important hypotheses that deserve to be evaluated as
primary hypotheses of interest in purposely designed studies,
rather than as secondary analyses in studies implemented for other
purposes such as the present study.
Conclusion
The present findings suggest that an HbA1c target of less than
6.5% or 48 mmol/mol might be too low for some patients and
large reductions, or increases, in HbA1c levels should be
approached cautiously. The findings also point to potential age-
related differences in HbA1c levels and mortality rates with
younger diabetes patients being at relatively greater risk of
mortality associated with low HbA1c levels even though absolute
risks are smaller at young ages. However, this finding needs
replication in future studies before making any definitive
recommendations regarding the development of different HbA1c
treatment targets for younger and older age diabetes patients.
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Table 4. Association between mortality and HbA1c, stratified by age group.
Model Age group (years)
,55 55–64 65–74 75–84 85+
COMPLETE CASE
Matched OR
Number of matched pairs 179 793 2353 3818 2098
,6.5%a 2.16 (1.31, 3.56) 1.51 (1.20, 1.91) 1.31 (1.15, 1.50) 1.19 (1.08, 1.31) 1.03 (0.91, 1.18)
.9.0%a 1.59 (0.91, 2.76) 1.65 (1.26, 2.15) 1.93 (1.59, 2.33) 1.62 (1.37, 1.91) 1.28 (1.02, 1.62)
Adjusted ORb
Number of matched pairs 164 737 2149 3307 1545
,6.5% a 2.05 (0.83, 5.06) 1.67 (1.14,2.46) 1.37 (1.12, 1.67) 1.19 (1.03, 1.37) 1.05 (0.87, 1.26)
.9.0%a 1.72 (0.76, 3.90) 1.84 (1.19, 2.84) 1.89 (1.43, 2.50) 1.60 (1.27, 2.02) 1.28 (0.92, 1.77)
MULTIPLE IMPUTATION
Number of matched pairs 432 1378 3842 6496 4437
Matched OR
,6.5%a 1.70 (1.19, 2.43) 1.32 (1.09, 1.60) 1.16 (1.04, 1.30) 1.11 (1.03, 1.21) 1.08 (0.98, 1.19)
.9.0%a 1.34 (0.89, 2.00) 1.49 (1.18, 1.87) 1.60 (1.37, 1.87) 1.41 (1.23, 1.62) 1.20 (1.01, 1.42)
Adjusted ORb
,6.5%a 1.53 (0.84, 2.79) 1.42 (1.04, 1.92) 1.19 (1.01, 1.41) 1.08 (0.96, 1.21) 1.04 (0.92, 1.17)
.9.0%a 1.20 (0.70, 2.07) 1.64 (1.13, 2.38) 1.46 (1.19, 1.80) 1.29 (1.08, 1.53) 1.15 (0.94, 1.41)
Figures are odds ratios (95% confidence intervals).
a6.5% to 9.0% as reference category;
badjusted for comorbidity, lipid lowering medication, smoking, BMI and diabetes drug utilisation.
doi:10.1371/journal.pone.0068008.t004
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